The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More
NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the… Read More
Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. IL-23 plays a critical role in pathogenic T-cell activation… Read More
The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the… Read More
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President… Read More
BioInnovation Institute (BII), life science incubator, has announced the addition of six companies who will receive additional financial support through its Venture House programme, created to further support former Venture Lab companies through their next phase of growth. Three of these are key to the advancement of gene therapies,… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Ahmed Mousa, CEO… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Ahmed Mousa, CEO… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More
Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services. Ginkgo provides R&D services across industries, including in biopharma, and will incorporate Patch’s machine learning models and downstream assays into its existing platform, making new… Read More
This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More
This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable,… Read More
Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and… Read More
CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology… Read More
